SAREPTA THERAPEUTICS INC (SRPT) Stock Fundamental Analysis
USA - NASDAQ:SRPT - US8036071004 - Common Stock
17.63 USD
-0.01 (-0.06%)
17.59 USD
-0.04 (-0.23%)
We assign a fundamental rating of 3 out of 10 to SRPT. SRPT was compared to 535 industry peers in the Biotechnology industry. Both the profitability and financial health of SRPT have multiple concerns. SRPT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SRPT had negative earnings in the past year.
In the past year SRPT has reported a negative cash flow from operations.
In the past 5 years SRPT reported 4 times negative net income.
In the past 5 years SRPT reported 4 times negative operating cash flow.
1.2 Ratios
SRPT has a Return On Assets of -1.57%. This is amongst the best in the industry. SRPT outperforms 88.76% of its industry peers.
SRPT's Return On Equity of -4.27% is amongst the best of the industry. SRPT outperforms 90.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.57% | ||
| ROE | -4.27% | ||
| ROIC | N/A |
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SRPT's Gross Margin of 79.28% is amongst the best of the industry. SRPT outperforms 84.64% of its industry peers.
In the last couple of years the Gross Margin of SRPT has remained more or less at the same level.
SRPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
2. Health
2.1 Basic Checks
SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SRPT has been increased compared to 1 year ago.
Compared to 5 years ago, SRPT has more shares outstanding
Compared to 1 year ago, SRPT has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.02, we must say that SRPT is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.02, SRPT perfoms like the industry average, outperforming 59.93% of the companies in the same industry.
A Debt/Equity ratio of 0.84 indicates that SRPT is somewhat dependend on debt financing.
SRPT has a Debt to Equity ratio of 0.84. This is in the lower half of the industry: SRPT underperforms 75.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.02 |
ROIC/WACCN/A
WACC7.2%
2.3 Liquidity
SRPT has a Current Ratio of 2.89. This indicates that SRPT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.89, SRPT is doing worse than 65.17% of the companies in the same industry.
SRPT has a Quick Ratio of 1.81. This is a normal value and indicates that SRPT is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of SRPT (1.81) is worse than 76.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.89 | ||
| Quick Ratio | 1.81 |
3. Growth
3.1 Past
The earnings per share for SRPT have decreased strongly by -197.60% in the last year.
Looking at the last year, SRPT shows a very strong growth in Revenue. The Revenue has grown by 52.97%.
The Revenue has been growing by 37.94% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
Revenue 1Y (TTM)52.97%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%
3.2 Future
The Earnings Per Share is expected to grow by 7.24% on average over the next years.
SRPT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.07% yearly.
EPS Next Y-292.84%
EPS Next 2Y3.1%
EPS Next 3Y2.13%
EPS Next 5Y7.24%
Revenue Next Year9.8%
Revenue Next 2Y-7.51%
Revenue Next 3Y-7.56%
Revenue Next 5Y-5.07%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SRPT. In the last year negative earnings were reported.
SRPT is valuated cheaply with a Price/Forward Earnings ratio of 7.27.
SRPT's Price/Forward Earnings ratio is rather cheap when compared to the industry. SRPT is cheaper than 98.31% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of SRPT to the average of the S&P500 Index (32.68), we can say SRPT is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.27 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SRPT is valued cheaper than 91.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 47.2 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.1%
EPS Next 3Y2.13%
5. Dividend
5.1 Amount
No dividends for SRPT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
17.63
-0.01 (-0.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners81.76%
Inst Owner Change-2.78%
Ins Owners4.63%
Ins Owner Change11.51%
Market Cap1.85B
Revenue(TTM)1.90B
Net Income(TTM)-57.96M
Analysts68
Price Target33.01 (87.24%)
Short Float %17.72%
Short Ratio2.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-114.71%
Min EPS beat(2)-376.26%
Max EPS beat(2)146.84%
EPS beat(4)2
Avg EPS beat(4)24.21%
Min EPS beat(4)-376.26%
Max EPS beat(4)348.76%
EPS beat(8)6
Avg EPS beat(8)617.4%
EPS beat(12)8
Avg EPS beat(12)384.79%
EPS beat(16)10
Avg EPS beat(16)285.72%
Revenue beat(2)2
Avg Revenue beat(2)9.95%
Min Revenue beat(2)6.86%
Max Revenue beat(2)13.04%
Revenue beat(4)4
Avg Revenue beat(4)8.67%
Min Revenue beat(4)2.86%
Max Revenue beat(4)13.04%
Revenue beat(8)7
Avg Revenue beat(8)5.95%
Revenue beat(12)9
Avg Revenue beat(12)3.94%
Revenue beat(16)12
Avg Revenue beat(16)3.6%
PT rev (1m)0.25%
PT rev (3m)3.87%
EPS NQ rev (1m)-3.78%
EPS NQ rev (3m)-27.14%
EPS NY rev (1m)1.99%
EPS NY rev (3m)-5.44%
Revenue NQ rev (1m)2.72%
Revenue NQ rev (3m)-1.67%
Revenue NY rev (1m)0.72%
Revenue NY rev (3m)6.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.27 | ||
| P/S | 0.74 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.36 | ||
| P/tB | 1.39 | ||
| EV/EBITDA | 47.2 |
EPS(TTM)-1.22
EYN/A
EPS(NY)2.42
Fwd EY13.75%
FCF(TTM)-4.34
FCFYN/A
OCF(TTM)-2.87
OCFYN/A
SpS23.71
BVpS12.97
TBVpS12.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.57% | ||
| ROE | -4.27% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.28% | ||
| FCFM | N/A |
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score2
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 28.38 | ||
| Cap/Depr | 372.98% | ||
| Cap/Sales | 6.17% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.89 | ||
| Quick Ratio | 1.81 | ||
| Altman-Z | 0.02 |
F-Score2
WACC7.2%
ROIC/WACCN/A
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
EPS Next Y-292.84%
EPS Next 2Y3.1%
EPS Next 3Y2.13%
EPS Next 5Y7.24%
Revenue 1Y (TTM)52.97%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%
Revenue Next Year9.8%
Revenue Next 2Y-7.51%
Revenue Next 3Y-7.56%
Revenue Next 5Y-5.07%
EBIT growth 1Y-102.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-229.84%
EBIT Next 3Y13.2%
EBIT Next 5Y10.53%
FCF growth 1Y15.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.48%
OCF growth 3YN/A
OCF growth 5YN/A
SAREPTA THERAPEUTICS INC / SRPT FAQ
What is the ChartMill fundamental rating of SAREPTA THERAPEUTICS INC (SRPT) stock?
ChartMill assigns a fundamental rating of 3 / 10 to SRPT.
What is the valuation status of SAREPTA THERAPEUTICS INC (SRPT) stock?
ChartMill assigns a valuation rating of 3 / 10 to SAREPTA THERAPEUTICS INC (SRPT). This can be considered as Overvalued.
How profitable is SAREPTA THERAPEUTICS INC (SRPT) stock?
SAREPTA THERAPEUTICS INC (SRPT) has a profitability rating of 3 / 10.
What is the earnings growth outlook for SAREPTA THERAPEUTICS INC?
The Earnings per Share (EPS) of SAREPTA THERAPEUTICS INC (SRPT) is expected to decline by -292.84% in the next year.